- Home
- CLRB vs BESS Comparison
CLRB vs BESS Comparison
Compare CLRB & BESS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CLRB | BESS |
|---|---|---|
| Founded | 2002 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.5M | 27.5M |
| IPO Year | 2008 | 2022 |
Fundamental Metrics
Financial Performance| Metric | CLRB | BESS |
|---|---|---|
| Price | $2.51 | $2.81 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | 26.0K | ★ 66.4K |
| Earning Date | 05-08-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $168,880.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.20 | $2.00 |
| 52 Week High | $6.52 | $6.45 |
Technical Indicators
Market Signals| Indicator | CLRB | BESS |
|---|---|---|
| Relative Strength Index (RSI) | 45.21 | 40.59 |
| Support Level | $2.44 | $2.72 |
| Resistance Level | $2.70 | $3.15 |
| Average True Range (ATR) | 0.10 | 0.33 |
| MACD | -0.00 | -0.05 |
| Stochastic Oscillator | 24.00 | 0.00 |
Price Performance
Historical ComparisonAbout CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. The products under development include Iopofosine, CLR 121125 ,CLR 121225 and others. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.
About BESS Bimergen Energy Corporation Common Stock
Bimergen Energy Corp is a renewable energy project developer that enables the clean energy transition and provides critical grid stability via solutions across a range of applications through portfolio of utility-scale Battery Energy Storage System (BESS) and solar development projects. Its portfolio includes approximately 23 development-stage utility-scale BESS projects with a projected total storage capacity of around 1.965 gigawatts (GW) and approximately 13 development-stage solar energy projects expected to generate around 1.640 GW upon completion and operation.